Wydanie 2/2013
str. 63

Leczenie jaskry a powierzchnia oka – konsekwencje wyboru metody terapeutycznej

Glaucoma Treatment and Ocular Surface – Consequences of the Therapeutic Method Choice

Joanna Wierzbowska

Klinika Okulistyki Wojskowego Instytutu Medycznego w Warszawie
Kierownik: dr hab. n. med. Marek Rękas, prof. nadzw. WIM


Summary: Glaucoma therapy is life-long and topical antiglaucoma agents used over long time affects the biology of the eye, especially the ocular surface. The majority of glaucoma patients throughout the world administer preservative-containing hypotensive eye-drops. Chronic multiple-drug therapy is detrimental to the conjunctival status and filtration surgery success. The impact of both the active ingredients and preservatives (benzalkonium chloride and the newly developed preservatives) on cornea and conjunctiva were described in detail. The findings of the main clinical trials on switching from preserved to preservative-free therapy were mentioned. Finally, adherence and persistence with chronic pharmacotherapy are essential to prevent glaucoma progression. The risk factors for poor adherence in glaucoma are multifactorial and they were discussed as well.

Słowa kluczowe: choroba powierzchni oka, neuropatia jaskrowa, chlorek benzalkonium.

Keywords: ocular surface disease, glaucomatous optic neuropathy, benzalkonium chloride.


powrót

REDAKCJA NIE UDZIELA PORAD MEDYCZNYCH I NIE POŚREDNICZY W KONSULTACJACH PACJENTÓW Z LEKARZAMI